PRELUDE THERAPEUTICS INC Payments of Stock Issuance Costs
PRELUDE THERAPEUTICS INC (PRLD) reported Payments of Stock Issuance Costs of $4.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for the quarter ending 2026-06-30 was $4.37M.
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for the quarter ending 2026-03-31 was $294.00K.
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for fiscal 2024 was $110.00K, a 96.07% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for fiscal 2023 was $2.80M.
- PRELUDE THERAPEUTICS INC payments of stock issuance costs for fiscal 2021 was $303.00K, a 2425.00% increase from fiscal 2020.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.66M 10-Q · filed 2026-08-11 | $4.66M derived: sum of 3 quarters · filed 2026-08-11 | $4.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $294.00K 10-Q · filed 2026-05-12 | $294.00K derived: sum of 2 quarters · filed 2026-05-12 | $294.00K derived: sum of 3 quarters · filed 2026-05-12 | $294.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $26.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $26.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $26.00K derived: sum of 2 quarters · filed 2026-03-10 | $110.00K 10-K · filed 2026-03-10 | |
| 2024-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $110.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $84.00K 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $2.80M 10-K · filed 2025-03-10 | |||
| 2023-06-30 | $2.60M 10-Q · filed 2024-11-06 | $2.90M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $297.00K 10-Q · filed 2024-05-07 | |||
| 2021-12-31 | $303.00K 10-K · filed 2023-03-15 | |||
| 2020-12-31 | $12.00K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |